CAS: 2562-52-9; 2,6,8-Trichloro-7H-Purine
该化合物是一种氯化净化衍生物,在有机合成和制药研究中广泛用作多用途中间体,其反应式三氯替代结构能够选择性地发挥功能,使其对制备纯基化合物,包括核分子类比和潜在的治疗剂具有价值.该化合物在核哲学替代反应中表现出高度的回弹性,允许在2-,6-或8个位置有效衍生.在标准储存条件下保持稳定,并符合各种反应条件,进一步提高其在药用化学和热循环合成中的效用.研究人员使用2,6,8-三氯丙烯作为开发生物活性分子,特别是在抗病毒和抗癌药物发现方面的关键构件.
物理性质
MSDS等安全信息
上下游产品
2,6-dichloro-7,9-dihydro-purin-8-one uric Acid 8-chloroxanthine trichlorophosphate (9)H-purine2,8-dichloro-6-morpholin-4-yl-7(9)H-purine H-purin-6-yl)-dimethyl-amine(2,8-dichloro-7(9)H-purin-6-yl)-dimethyl-amine 9-methyl-2,6,8-trichloropurine 2,6,8-trichloro-7-methylpurine合成工艺路线路线简述
📜8-氯-1H-嘌呤-2,6(3H,7H)-二酮置于n,N-二甲基苯胺,三氯氧磷体系中,化学反应生成2,6,8-三氯嘌呤
参考文献:Garkuscha,Zhurnal Obshchei Khimii,1957,Vol. 27,P. 1712,1715;Engl.Ausg.S.1783,1785
标题:Garkuscha,Zhurnal Obshchei Khimii,1957,Vol. 27,P. 1712,1715;Engl.Ausg.S.1783,1785
专利信息
专利号:US-2023104311-A1
优先权日:2020-02-17
标题:Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
发明人：HERDEWIJN PIET; GROAZ ELISABETTA; QINGFENG LI
权利人:UNIV LEUVEN KATH
摘要:The present invention relates to the synthesis of 6-substituted 7-deazapurines and their corresponding nucleosides by coupling aryl or alkyl Grignard reagents with halogenated purine nucleosides in the presence of iron or an iron/copper mixture such as Fe(acac)3/CuI. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:G.B. Barlin and N.B. Chapman. J. Chem. Soc. 1965, 3017.
📝 需求与反馈
尽可能描述清楚需求与问题信息
